VanderbiltHealth.com: For Patients and Visitors
Vanderbilt University Medical Center: For Employees, Researchers, and Students

Collaborators

 

The J.B. Marshall Laboratory for Neurovascular Therapeutics originated from a partnership between several Vanderbilt departments and BBBD teams at other academic medical centers.  Collaboration remains one of our core principles, and we are honored to be able to work with the following outstanding researchers and clinicians.

Lori Jordan, M.D., Ph.D.

Assistant Professor of Neurology

Dr. Jordan earned her B.S. in Biology from the College of William and Mary in Virginia, graduating Phi Beta Kappa. She then received her medical degree (M.D.) from the University of Oklahoma and her Ph.D. in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. She completed residencies in Pediatrics and Pediatric Neurology as well as a fellowship in Cerebrovascular Neurology (Stroke) at The Johns Hopkins Hospital. After completing her training, Dr. Jordan was on staff at John Hopkins Hospital for several years. There, she was Director of the Pediatric Stroke Program and Co-Director of the Pediatric Neurovascular Center. In 2011, she joined the faculty at Vanderbilt in the divisions of Pediatric Neurology and Stroke in the Department of Neurology. Dr. Jordan is Assistant Professor of Neurology and Pediatrics. She is board certified in Neurology with Special Qualification in Child Neurology and in Pediatrics.

 
Dr. Jordan has particular expertise in ischemic stroke, brain hemorrhage, vascular malformations and the neurological complications of sickle cell disease. She is one of only a handful of child neurologists in the world with formal, subspecialty training in cerebrovascular neurology. She is Director of the Pediatric Stroke Program at Monroe Carell, Jr. Children's Hospital at Vanderbilt University Medical Center.
 
Dr. Jordan’s research focuses on predicting and improving outcome after hemorrhagic and ischemic stroke in children.
 
 

BethAnn McLaughlin, Ph.D.

Assistant Professor of Neurology
Assistant Professor of Pharmacology

Dr. McLaughlin received her bachelor’s degree in Biopsychology from Skidmore College. She then received her Ph.D. in Neurological Sciences from the University of Pennsylvania. Dr. McLaughlin subsequently completed a postdoctoral fellowship in the Department of Neurobiology at the University of Pittsburgh. In 2002, Dr. McLaughlin joined the faculty of the Vanderbilt University School of Medicine where she currently has appointments in the Department of Neurology and the Department of Pharmacology. Dr. McLaughlin is also an Investigator in the Vanderbilt Kennedy Center for Research on Human Development, where she is a member of the Leadership Council.
 
Dr. McLaughlin is interested in understanding the mechanisms that contribute to cell vulnerability to acute and chronic insults. To this end, her lab uses a variety of in vitro and in vivo model systems to understand the cellular and molecular responses to neuronal stress in an attempt to develop clinically relevant neuroprotective strategies.

 

OHSU Blood-Brain Barrier Program

The International Blood-Brain Barrier Disruption Program originated in the early 1980s under the leadership of Edward A. Neuwelt, M.D. (right), a neurosurgeon at the Oregon Health and Science University. Dr. Neuwelt developed an innovative method for improving the delivery of cancer therapies by opening the blood-brain barrier. Since that time, the Blood-Brain Barrier Program at OHSU has grown to become a thriving team of physicians, nurse practitioners, nurses, and preclinical researchers who address a wide range of needs for patients with brain tumors.  Dr. Neuwelt and his team have used blood-brain barrier disruption (BBBD) and intra-arterial chemotherapy to treat primary central nervous system lymphoma patients for almost thirty years. In addition, they have employed BBBD in the treatment of primitive neuro-ectodermal tumors, germ cell tumors, and glioblastoma multiforme. Pre-clinical research at the OHSU Blood-Brain Barrier Program under the leadership of Leslie Muldoon, Ph.D. has characterized the efficacy and safety of BBBD-enhanced chemotherapy using numerous drugs and protective agents on a range of tumor targets.

 
The International Blood-Brain Barrier Program has extensively advocated for the importance of addressing the blood-brain barrier in the delivery of drugs to central nervous system tumors. Since they began, several institutions worldwide have joined clinical and pre-clinical research on BBBD and intra-arterial therapy delivery. In August 2010, the Singer Lab became a member of this group.
Copyright © 2013 by Vanderbilt University Medical Center    |    1211 Medical Center Drive    |    Nashville, TN 37232    |    (615) 322-5000
Vanderbilt University is committed to principles of equal opportunity and affirmative action.
This page was last updated November 21, 2011 and is maintained by Jake Martin